N. Andreu

Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study.

H. Maillard, R. Lassalle, A. Taïeb, 2021, Journal of Investigative Dermatology.

Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata

A. Taïeb, J. Seneschal, C. Jacquemin, 2018, The British journal of dermatology.

Factors associated with perceived-stress in patients of the vitiligo ComPaRe e-cohort.

P. Ravaud, E. Sbidian, K. Ezzedine, 2021, Journal of American Academy of Dermatology.

Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti–programmed cell death-1 therapies for melanoma: A cross-sectional study

T. Barnetche, M. Beylot-Barry, S. Prey, 2021, JAAD international.

Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a cross‐sectional study

K. Ezzedine, J. Seneschal, J. Shourick, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Vitiligo Treatment Impact score (VITs): development and validation of a vitiligo burden of treatment questionnaire using the ComPaRe Vitiligo e‐cohort

P. Ravaud, K. Ezzedine, J. Seneschal, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

Assessment of VASI, Facial-VASI and VES scores using standardized photography of vitiligo.

T. Barnetche, J. Seneschal, A. Taieb, 2022, British Journal of Dermatology.